Jay S. Skyler

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C. Herold, Brian N. Bundy, S. Alice Long et al. · New England Journal of Medicine · 2019 · 1.1K citations · Full text

Medicine, Immunology, Internal Medicine +17

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

Life Sciences, Endocrinology, Immunology +16

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

Jay S. Skyler, Richard M. Bergenstal, Robert O. Bonow et al. · Diabetes Care · 2008 · 884 citations · Full text

Medicine, Internal Medicine, Diabetology +16

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Tihamer Orban, Brian N. Bundy, Dorothy J. Becker et al. · The Lancet · 2011 · 601 citations

Medicine, Endocrinology, Pharmacotherapy +9

C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

Jerry P. Palmer, G. Alexander Fleming, Carla J. Greenbaum et al. · Diabetes · 2004 · 484 citations · Full text

Medicine, Endocrinology, Immunology +17